Cara Therapeutics Inc. (CARA) 9.93 $CARA
Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced it is sponsoring and participating in a lunch symposium titled, "Kappa: Myths / misconceptions, and moving beyond Mu," at the 25 Annual Clinical Meeting of the American Academy of Pain Management. Leading pain experts will discuss the evolving medical and regulatory climate around mu-opioids and how kappa agonists may become an important treatment option. Experts will also discuss the Phase 2 data from Cara's clinical program of CR845, a peripherally acting kappa receptor agonist for acute pain, as well as the future of analgesia.
Cara Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2014.
Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced the dosing of the first dialysis patients in a Phase II trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015.
Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, August 7, 2014, at 4:30 p.m. ET to report second quarter 2014 financial results and provide a corporate update.
Cara Therapeutics Initiates Human Abuse Liability Trial of CR845
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a human abuse liability (HAL) trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845. The company expects to report top-line data from this trial in the fourth quarter of 2014.
Cara Therapeutics receives milestone payment for completing its Phase 1 single and multiple ascending dose trial of IV CR845 in Japanese population
M2 - Thu Jul 17, 8:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) revealed on Wednesday the receipt of a USD500,000 milestone payment from Maruishi Pharmaceutical Company for the completion of its Phase 1 clinical trial of the IV formulation of CR845 in Japan.
Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical Company, Ltd., for the completion of Maruishi's Phase 1 clinical trial of the I.V. formulation of Cara's novel kappa opioid agonist, CR845, in Japan.
3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
GlobeNewswire - Tue Jun 24, 7:07AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Dr. Robert Medve has been named Chief Medical Officer, effective immediately. Dr. Medve will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:44AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares surge over 19% on the day.
Why Cara Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 20, 12:38PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cara Therapeutics , a clinical-stage...
Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
PR Newswire - Fri Jun 20, 7:10AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (Nasdaq: CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.
Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Wed Jun 18, 7:08AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.
'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced it is sponsoring and participating in a lunch symposium titled, "Kappa: Myths / misconceptions, and moving beyond Mu," at the 25 Annual Clinical Meeting of the American Academy of Pain Management. Leading pain experts will discuss the evolving medical and regulatory climate around mu-opioids and how kappa agonists may become an important treatment option. Experts will also discuss the Phase 2 data from Cara's clinical program of CR845, a peripherally acting kappa receptor agonist for acute pain, as well as the future of analgesia.
Cara Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2014.
Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced the dosing of the first dialysis patients in a Phase II trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015.
Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, August 7, 2014, at 4:30 p.m. ET to report second quarter 2014 financial results and provide a corporate update.
Cara Therapeutics Initiates Human Abuse Liability Trial of CR845
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a human abuse liability (HAL) trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845. The company expects to report top-line data from this trial in the fourth quarter of 2014.
Cara Therapeutics receives milestone payment for completing its Phase 1 single and multiple ascending dose trial of IV CR845 in Japanese population
M2 - Thu Jul 17, 8:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) revealed on Wednesday the receipt of a USD500,000 milestone payment from Maruishi Pharmaceutical Company for the completion of its Phase 1 clinical trial of the IV formulation of CR845 in Japan.
Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical Company, Ltd., for the completion of Maruishi's Phase 1 clinical trial of the I.V. formulation of Cara's novel kappa opioid agonist, CR845, in Japan.
3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
GlobeNewswire - Tue Jun 24, 7:07AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Dr. Robert Medve has been named Chief Medical Officer, effective immediately. Dr. Medve will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:44AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares surge over 19% on the day.
Why Cara Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 20, 12:38PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cara Therapeutics , a clinical-stage...
Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
PR Newswire - Fri Jun 20, 7:10AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (Nasdaq: CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.
Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Wed Jun 18, 7:08AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.
'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
